Chris Schott
Stock Analyst at JP Morgan
(4.05)
# 540
Out of 5,090 analysts
149
Total ratings
66.02%
Success rate
7.07%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,150 | $1,014.49 | +13.36% | 23 | Nov 18, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $7.14 | +68.07% | 3 | Nov 11, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $26 → $28 | $28.41 | -1.44% | 19 | Nov 6, 2025 | |
| PRGO Perrigo Company | Downgrades: Neutral | $32 → $20 | $13.49 | +48.26% | 13 | Nov 6, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $120.41 | +66.10% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $717.35 | +8.04% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $228.71 | +13.68% | 4 | Nov 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $122.42 | +22.53% | 8 | Oct 31, 2025 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $18 → $24 | $21.99 | +9.14% | 4 | Oct 7, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $12 → $14 | $11.89 | +17.75% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $950 → $800 | $722.83 | +10.68% | 8 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $181.82 | -3.75% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $39.17 | +7.24% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $340.33 | -20.66% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $25.70 | +32.30% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $100.89 | +23.90% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $10.73 | +30.54% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.23 | +794.31% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.38 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $51.95 | +50.14% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $1.05 | +90,376.19% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.61 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $23.97 | +108.59% | 3 | Nov 2, 2018 |
Eli Lilly and Company
Nov 18, 2025
Maintains: Overweight
Price Target: $1,050 → $1,150
Current: $1,014.49
Upside: +13.36%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $7.14
Upside: +68.07%
Teva Pharmaceutical Industries
Nov 6, 2025
Maintains: Overweight
Price Target: $26 → $28
Current: $28.41
Upside: -1.44%
Perrigo Company
Nov 6, 2025
Downgrades: Neutral
Price Target: $32 → $20
Current: $13.49
Upside: +48.26%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $120.41
Upside: +66.10%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $717.35
Upside: +8.04%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $228.71
Upside: +13.68%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $122.42
Upside: +22.53%
Elanco Animal Health
Oct 7, 2025
Upgrades: Overweight
Price Target: $18 → $24
Current: $21.99
Upside: +9.14%
Amneal Pharmaceuticals
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $11.89
Upside: +17.75%
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $722.83
Upside: +10.68%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $181.82
Upside: -3.75%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $39.17
Upside: +7.24%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $340.33
Upside: -20.66%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $25.70
Upside: +32.30%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $100.89
Upside: +23.90%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $10.73
Upside: +30.54%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.23
Upside: +794.31%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.38
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $51.95
Upside: +50.14%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $1.05
Upside: +90,376.19%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $23.97
Upside: +108.59%